SEC Tracker
Get the app
EVFM · XBRL financial data

Evofem Biosciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (EVFM's year ends in late December)

In millions of dollarsOct 31, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers—5*4447*15510*13
Cost of goods and services sold—1*1112*0113*01
Research and development—1*1001*——————
General and administrative—3*3233*2221*22
Operating income (loss)—(3)*(3)(1)(2)(1)*0(1)13*(5)(2)
Interest income—0*0000*0000*00
Interest expense—1*11*1*1*11*1*1*11*
Income tax expense (benefit)—0*—0(0)——0(0)(0)*(0)0*
Net income (loss)—(2)*(5)1(2)(3)*1(2)(2)3*(5)(11)
Earnings per share, basic USD per share——(0.16)0.02(0.02)—0.01(0.02)(0.01)0.02*(0.04)(0.08)
Earnings per share, diluted USD per share——(0.16)0.00(0.02)—0.00(0.02)(0.01)—(0.04)(0.08)
Weighted average shares, basic millions of shares——316796—113116120146*133137
Weighted average shares, diluted millions of shares——311,61496—6,040116120—133137

Balance sheet

CSV

Fiscal quarters (EVFM's year ends in late December)

In millions of dollarsOct 31, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents—11111011110
Accounts receivable—6455101541212
Inventory—21112222122
Prepaid and other current assets—11111111111
Total current assets—9779146981566
Property and equipment, net—11110000000
Right-of-use asset—00000000000
Total assets—118924241314142078
Accounts payable—1716161716111212131212
Accrued liabilities—45556331112
Total current liabilities—7274737680717478857989
Lease liability, non-current—00000000000
Total liabilities—7274739090787984908090
Accumulated deficit—(889)(894)(892)(895)(898)(897)(898)(900)(897)(903)(914)
Total stockholders' equity—(67)(71)(69)(71)(71)(70)(70)(75)(74)(78)(88)
Total liabilities and equity—118924241314142078
Common shares outstanding (cover page) millions of shares114662100100113113119127133133133

Cash flows

CSV

Fiscal quarters (EVFM's year ends in late December)

In millions of dollarsOct 31, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)—(2)*(5)1(2)(3)*1(2)(2)3*(5)(11)
Stock-based compensation—0*00*0*0*00*0*0*00*
Net cash from operating activities—(0)*0(1)*(0)*(2)*1(3)*0*0*2(3)*
Purchases of property and equipment—0*00*0*0*——0*0*00*
Net cash from investing activities—0*(0)0*(1)*(0)*(0)(0)*0*(0)*(0)0*
Proceeds from long-term debt—0*——————————
Repayments of long-term debt—0*——0*———————
Net cash from financing activities—0*——1*2*(0)3*(0)*(0)*(0)1*
Net change in cash—0*00*0*0*0(0)*0*(0)*2(2)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Evofem Biosciences0.32.6(3.1)*132.5M0.1 quarters 10-QJun 30, 2026
Agentix0not reported(0)40.1M0.0 quarters 10-QJun 30, 2026
Regen BioPharma00.1(0)*1.7B0.0 quarters 10-QJun 30, 2026
Twinlab Consolidated Holdings0not reported(0.9)*259.1M0.0 quarters 10-KDec 31, 2024
Galera Therapeutics5.5not reported(0.9)160.4M6.3 quarters 10-QMar 31, 2026
ProtoKinetix0not reported0*411.6M— 10-KDec 31, 2025
Hepion Pharmaceuticals1.6not reported(1.4)*90.2M1.2 quarters 10-QJun 30, 2026
China Foods Holdings00(0.1)*20.3M0.2 quarters 10-QJun 30, 2026
Mosaic ImmunoEngineering0not reported(0)*7.2M0.6 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.